Capital Insight Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-86,582
| Closed | -$2.4M | – | 166 |
|
|
2024
Q1 | $2.4M | Sell |
86,582
-2,580
| -3% | -$71.6K | 0.45% | 69 |
|
|
2023
Q4 | $2.57M | Buy |
89,162
+903
| +1% | +$27.3K | 0.53% | 66 |
|
|
2023
Q3 | $2.93M | Buy |
88,259
+2,576
| +3% | +$91.1K | 0.67% | 50 |
|
|
2023
Q2 | $3.14M | Sell |
85,683
-41
| -0% | -$1.6K | 0.7% | 48 |
|
|
2023
Q1 | $3.5M | Buy |
85,724
+3,656
| +4% | +$158K | 0.82% | 36 |
|
|
2022
Q4 | $4.21M | Buy |
82,068
+7,062
| +9% | +$339K | 1.09% | 23 |
|
|
2022
Q3 | $3.28M | Buy |
75,006
+1,059
| +1% | +$51.5K | 0.88% | 34 |
|
|
2022
Q2 | $3.88M | Buy |
73,947
+1,176
| +2% | +$59.9K | 0.91% | 33 |
|
|
2022
Q1 | $3.77M | Sell |
72,771
-3,024
| -4% | -$157K | 0.77% | 42 |
|
|
2021
Q4 | $4.48M | Buy |
75,795
+430
| +0.6% | +$21.3K | 0.91% | 33 |
|
|
2021
Q3 | $3.24M | Buy |
75,365
+970
| +1% | +$43K | 0.7% | 48 |
|
|
2021
Q2 | $2.91M | Buy |
74,395
+2,461
| +3% | +$95.7K | 0.66% | 59 |
|
|
2021
Q1 | $2.61M | Buy |
71,934
+20,382
| +40% | +$724K | 0.63% | 62 |
|
|
2020
Q4 | $1.9M | Sell |
51,552
-2,339
| -4% | -$85.8K | 0.48% | 80 |
|
|
2020
Q3 | $1.88M | Buy |
53,891
+451
| +0.8% | +$15.8K | 0.53% | 74 |
|
|
2020
Q2 | $1.66M | Buy |
53,440
+2,719
| +5% | +$92.4K | 0.52% | 69 |
|
|
2020
Q1 | $1.57M | Buy |
50,721
+2,978
| +6% | +$101K | 0.83% | 40 |
|
|
2019
Q4 | $1.77M | Sell |
47,743
-606
| -1% | -$21.6K | 0.82% | 39 |
|
|
2019
Q3 | $1.65M | Buy |
48,349
+79
| +0.2% | +$2.87K | 1.44% | 31 |
|
|
2019
Q2 | $1.98M | Sell |
48,270
-388
| -0.8% | -$15.4K | 1.72% | 24 |
|
|
2019
Q1 | $1.96M | Sell |
48,658
-1,474
| -3% | -$59K | 1.77% | 20 |
|
|
2018
Q4 | $2.08M | Buy |
50,132
+42
| +0.1% | +$1.74K | 2.14% | 12 |
|
|
2018
Q3 | $2.09M | Sell |
50,090
-53,642
| -52% | -$2.07M | 1.84% | 20 |
|
|
2018
Q2 | $3.57M | Buy |
103,732
+250
| +0.2% | +$8.54K | 2.94% | 5 |
|
|
2018
Q1 | $3.48M | Buy |
103,482
+2,069
| +2% | +$71.1K | 2.84% | 4 |
|
|
2017
Q4 | $3.48M | Buy |
101,413
+393
| +0.4% | +$13.4K | 2.73% | 5 |
|
|
2017
Q3 | $3.42M | Buy |
101,020
+4,738
| +5% | +$152K | 2.89% | 3 |
|
|
2017
Q2 | $3.07M | Sell |
96,282
-1,630
| -2% | -$51.4K | 2.72% | 5 |
|
|
2017
Q1 | $3.18M | Buy |
97,912
+16,082
| +20% | +$507K | 2.88% | 4 |
|
|
2016
Q4 | $2.52M | Sell |
81,830
-10,386
| -11% | -$317K | 2.5% | 11 |
|
|
2016
Q3 | $2.96M | Sell |
92,216
-13,459
| -13% | -$450K | 2.85% | 6 |
|
|
2016
Q2 | $3.53M | Buy |
105,675
+2,934
| +3% | +$93.6K | 3.35% | 4 |
|
|
2016
Q1 | $2.89M | Buy |
102,741
+2,077
| +2% | +$59.3K | 2.94% | 9 |
|
|
2015
Q4 | $3.08M | Sell |
100,664
-13,458
| -12% | -$423K | 3.12% | 7 |
|
|
2015
Q3 | $3.4M | Sell |
114,122
-121
| -0.1% | -$3.88K | 3.19% | 9 |
|
|
2015
Q2 | $3.63M | Buy |
+114,243
| New | +$3.72M | 3.07% | 7 |
|
Other funds holding PFE
Capital Insight Partners's PFE Position: Q2 2024 in Review
Capital Insight Partners sold out of Pfizer (PFE) in Q2 2024, closing a stake of 86,582 shares — an estimated $2.4M sold.
Capital Insight Partners first reported a position in PFE in Q2 2015 and held it in 36 quarters. The position peaked at $4.48M in Q4 2021. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Capital Insight Partners reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
- Capital Insight Partners sold 86,582 Pfizer shares in Q2 2024, an estimated $2.4M.
- Capital Insight Partners first reported a position in Pfizer in Q2 2015 and held it in 36 quarters.
- Capital Insight Partners's Pfizer position peaked at $4.48M in Q4 2021.
- 2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Capital Insight Partners's 13F filing for Q2 2024, filed 24 Jul 2024.